Greenwich LifeSciences (GLSI) Income from Continuing Operations (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Income from Continuing Operations of 17198292.0 for Q4 2025, down 314.23% on a QoQ basis from 4151845.0 in Q3 2025, and down 5.48% year-over-year from 18195559.99 in Q4 2024.
Greenwich LifeSciences (GLSI) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 17198292.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 5.48% year-over-year to 17198292.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 28633777.0 (down 19.04% YoY) and the FY2025 annual result came in at 28633777.0, down 19.04% from the prior year.
- Income from Continuing Operations was 17198292.0 for Q4 2025 at Greenwich LifeSciences, down from 4151845.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 597008.0 in Q1 2021 and bottomed at 17198292.0 in Q4 2025.
- A 5-year average of 4433267.9 and a median of 2963537.5 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 511.25% — and 2023, when it soared 44.75%.
- Greenwich LifeSciences' Income from Continuing Operations stood at 3874993.0 in 2021, then tumbled by 52.98% to 5927876.0 in 2022, then decreased by 22.34% to 7251983.0 in 2023, then plunged by 124.83% to 16304661.0 in 2024, then decreased by 5.48% to 17198292.0 in 2025.
- Business Quant data shows GLSI's Income from Continuing Operations at 17198292.0 in Q4 2025, 4151845.0 in Q3 2025, and 4025278.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | -17.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.20 Mn |
| Sep 30, 2025 | -4.15 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -3.26 Mn |
| Dec 31, 2024 | -16.30 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -2.61 Mn |
| Mar 31, 2024 | -2.47 Mn |
| Dec 31, 2023 | -7.25 Mn |
| Sep 30, 2023 | -2.39 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Mar 31, 2023 | -2.12 Mn |
| Dec 31, 2022 | -5.93 Mn |
| Sep 30, 2022 | -4.33 Mn |
| Jun 30, 2022 | -2.59 Mn |
| Mar 31, 2022 | -3.65 Mn |
| Dec 31, 2021 | -3.87 Mn |
| Sep 30, 2021 | -863,118.00 |
| Jun 30, 2021 | -749,745.00 |
| Mar 31, 2021 | -597,008.00 |